Chemed (CHE)
(Delayed Data from NYSE)
$588.48 USD
+3.59 (0.61%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $589.25 +0.77 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$588.48 USD
+3.59 (0.61%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $589.25 +0.77 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.
Chemed (CHE) Surges 3.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Chemed (CHE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Chemed (CHE) Stock Now
by Zacks Equity Research
Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Chemed (CHE) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 6.68% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Chemed (CHE) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 3.75% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemed (CHE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADUS or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.
Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses
by Zacks Equity Research
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm
by Zacks Equity Research
The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.
Edwards (EW) States Long-Term Strategy, Provides 2022 View
by Zacks Equity Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.
CVS Health (CVS) New Alliance to Boost Digital Transformation
by Zacks Equity Research
CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
by Zacks Equity Research
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.